CAC Software vs ClearRead CT
AI Verdict
Choose CAC Software if…
Choose Imbio's CAC Software if your primary need is a highly specialized and detailed analysis of coronary artery calcification for cardiovascular risk assessment. This tool provides comprehensive quantification, including Agatston score, arterial age, and calcified lesion mass and volume, along with 3D visualizations, from non-contrast chest CTs.
View CAC Software →Choose ClearRead CT if…
Choose ClearRead CT if you require a comprehensive AI suite for cardiothoracic imaging that prioritizes both enhanced pulmonary nodule detection and coronary artery calcification analysis. This tool is ideal for practices seeking to improve diagnostic accuracy, reduce reading times by up to 36%, and streamline workflows through features like patented vessel suppression and automated nodule tracking.
View ClearRead CT →When choosing between Imbio’s CAC Software and Riverain Technologies’ ClearRead CT, physicians should consider their primary diagnostic focus. Imbio’s CAC Software excels in comprehensive coronary artery calcification analysis, providing detailed quantification including Agatston score, arterial age, calcified lesion mass, and volume, along with 3D visualizations. It’s specifically designed for cardiologists and radiologists focused on robust cardiovascular risk assessment from non-contrast chest CTs.
In contrast, ClearRead CT offers a broader AI suite for cardiothoracic health, with a strong emphasis on pulmonary nodule detection and characterization, alongside CAC scoring. Its patented vessel suppression technology and features for nodule tracking and comparison to prior exams make it particularly valuable for pulmonologists and radiologists managing oncology cases. The key practical difference lies in their core strengths: Imbio provides deeper, specialized CAC analysis, while ClearRead CT offers a more versatile platform for both cardiac and pulmonary findings, potentially streamlining workflows for practices with a dual focus.
Therefore, a physician whose primary need is in-depth, detailed coronary artery calcification assessment for cardiovascular risk stratification would likely find Imbio’s CAC Software more aligned with their requirements. Conversely, a physician or practice seeking an AI tool that enhances both pulmonary nodule detection and offers CAC scoring, aiming to improve diagnostic accuracy and reduce reading times across a wider range of cardiothoracic cases, would benefit more from ClearRead CT.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | CAC Software | ClearRead CT |
|---|---|---|
| Pricing | Contact for pricing | Contact for pricing |
| Deployment | Cloud, On-premise, Partner platforms | On-premise (stand-alone server, virtual machine) and Cloud |
| FDA Status | 1 AI-estimated | 1 AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
ClearRead CTClearRead CT (Tool B) demonstrates superior usability through its seamless PACS integration and documented ability to reduce reading times by up to 36%, allowing radiologists to stay within their primary viewing application. User testimonials highlight its ease of installation and efficient workflow, directly addressing common pain points in AI tool adoption. In contrast, CAC Software (Tool A) describes a 'minimal' user interface and command-line execution, which, while flexible for integration, may not offer the same direct user-friendliness for daily clinical interaction.
Clinical Value
ClearRead CTClearRead CT (Tool B) offers a broader clinical scope by providing both pulmonary nodule detection and coronary artery calcification (CAC) analysis, with a proven 29% reduction in missed actionable nodules. Its patented vessel suppression technology further enhances diagnostic accuracy for lung nodules. While CAC Software (Tool A) provides robust and validated CAC quantification with a high Cohen's kappa score, Tool B's dual functionality and quantified impact on nodule detection accuracy provide a more comprehensive clinical value.
Pricing & Value
ClearRead CTBoth tools require direct contact for pricing information, limiting transparency. However, ClearRead CT (Tool B) offers more insight into its pricing model, specifying options like a one-time license fee or subscription based on the number of analyses. This provides a clearer understanding of potential cost structures compared to CAC Software's (Tool A) generic 'contact for pricing' statement.
Enterprise Readiness
ClearRead CTBoth tools are FDA-cleared and support flexible deployment. While CAC Software (Tool A) explicitly states HIPAA compliance and BAA availability in its facts, ClearRead CT (Tool B) boasts ISO27001 certification and a large global customer base with over 400 customer locations, including successful integration in high-volume enterprises like SimonMed. This extensive real-world adoption and certification provide stronger evidence of robust enterprise readiness for Tool B.
Innovation
ClearRead CTBoth tools leverage AI and deep learning. However, ClearRead CT (Tool B) stands out with its 'Patented Vessel Suppression (Clear Visual Intelligence)' technology, a unique innovation that significantly improves nodule conspicuity. Its capabilities for automated nodule tracking and comparison to prior exams also demonstrate advanced innovation in workflow and longitudinal patient management, distinguishing it from Tool A's deep-learning based CAC analysis.
Support & Docs
ClearRead CTClearRead CT (Tool B) offers more comprehensive and transparent support resources, including specific customer service hotlines, email, and a dedicated support portal with FAQs, user manuals, and detailed documentation on workflows and system requirements. While CAC Software (Tool A) provides contact information and mentions documentation, Tool B's clearly outlined and readily accessible support infrastructure indicates a more robust commitment to user support.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | CAC Software | ClearRead CT |
|---|---|---|
| Tool Name | CAC Software | ClearRead CT |
| Company | Imbio | RIVERAIN TECHNOLOGIES |
| Primary Focus | Automated image post-processing algorithms to determine location and calculate amount of calcification within coronary arteries from non-contrast chest CT. | Enhancing pulmonary nodule detection and coronary artery calcification analysis in CT scans. |
| Key Feature: CAC Analysis Output | Outputs Agatston score, arterial age, calcified lesion mass and volume; Provides 3D visualizations and annotated images. | Coronary Artery Calcification (CAC) Scoring (ungated, non-contrast CTs). |
| Key Feature: Additional Capabilities | Supports risk assessment for coronary artery disease; Deep-learning based analysis. | Pulmonary Nodule Detection (solid, part-solid, ground glass); Patented Vessel Suppression; Nodule Characterization and Measurement; Automated Nodule Tracking and Comparison to Prior Exams. |
| Specialties | Cardiology, Radiology | Cardiology, Pulmonology, Radiology |
Videos
Demos, reviews, and walkthroughs featuring CAC Software and ClearRead CT.